Trials / Not Yet Recruiting
Not Yet RecruitingNCT06972615
Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy
A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- BLATAM · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
interventional study of intravesical chemotherapy and sistemic immunotherapy in NMIBC
Detailed description
patients will receive intrravesical chemotherapy every 3 weeks and systemic pembrolizumb every 6 week. for a total of 1 year of treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intravesical Chemotherapy docetaxel/gemcitabine | intravesical quimiotherapy plus intravenous immunotherapy |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2029-12-31
- Completion
- 2030-06-15
- First posted
- 2025-05-15
- Last updated
- 2026-02-17
Locations
1 site across 1 country: Argentina
Source: ClinicalTrials.gov record NCT06972615. Inclusion in this directory is not an endorsement.